Literature DB >> 23015725

Heparan sulfate facilitates Rift Valley fever virus entry into the cell.

S M de Boer1, J Kortekaas, C A M de Haan, P J M Rottier, R J M Moormann, B J Bosch.   

Abstract

Rift Valley fever virus (RVFV), an emerging arthropod-borne pathogen, has a broad host and cell tropism. Here we report that the glycosaminoglycan heparan sulfate, abundantly present on the surface of most animal cells, is required for efficient entry of RVFV. Entry was significantly reduced by preincubating the virus inoculum with highly sulfated heparin, by enzymatic removal of heparan sulfate from cells and in cells genetically deficient in heparan sulfate synthesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015725      PMCID: PMC3503077          DOI: 10.1128/JVI.01364-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Rift Valley fever: present status and risk to the Western Hemisphere.

Authors:  J A House; M J Turell; C A Mebus
Journal:  Ann N Y Acad Sci       Date:  1992-06-16       Impact factor: 5.691

2.  NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture.

Authors:  Sungyong Won; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Rift valley fever; I. The occurrence of human cases in Johannesburg.

Authors:  B MUNDEL; J GEAR
Journal:  S Afr Med J       Date:  1951-11-03

4.  Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor.

Authors:  Cornelis A M de Haan; Zhen Li; Eddie te Lintelo; Berend Jan Bosch; Bert Jan Haijema; Peter J M Rottier
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

6.  Chlorate--a potent inhibitor of protein sulfation in intact cells.

Authors:  P A Baeuerle; W B Huttner
Journal:  Biochem Biophys Res Commun       Date:  1986-12-15       Impact factor: 3.575

Review 7.  Sialic acid-specific lectins: occurrence, specificity and function.

Authors:  F Lehmann; E Tiralongo; J Tiralongo
Journal:  Cell Mol Life Sci       Date:  2006-06       Impact factor: 9.261

8.  beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure.

Authors:  I N Gavrilovskaya; M Shepley; R Shaw; M H Ginsberg; E R Mackow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor.

Authors:  W B Klimstra; K D Ryman; R E Johnston
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 10.  Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins.

Authors:  R E Hileman; J R Fromm; J M Weiler; R J Linhardt
Journal:  Bioessays       Date:  1998-02       Impact factor: 4.345

View more
  37 in total

1.  A Genome-Wide CRISPR-Cas9 Screen Reveals the Requirement of Host Cell Sulfation for Schmallenberg Virus Infection.

Authors:  Thiprampai Thamamongood; Andrea Aebischer; Valentina Wagner; Max W Chang; Roland Elling; Christopher Benner; Adolfo García-Sastre; Georg Kochs; Martin Beer; Martin Schwemmle
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Human astrocytic cells support persistent coxsackievirus B3 infection.

Authors:  Xiaowei Zhang; Zhenhua Zheng; Bo Shu; Xijuan Liu; Zhenfeng Zhang; Yan Liu; Bingke Bai; Qinxue Hu; Panyong Mao; Hanzhong Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Genome-wide small interfering RNA screens reveal VAMP3 as a novel host factor required for Uukuniemi virus late penetration.

Authors:  Roger Meier; Andrea Franceschini; Peter Horvath; Marilou Tetard; Roberta Mancini; Christian von Mering; Ari Helenius; Pierre-Yves Lozach
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 4.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

5.  Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition.

Authors:  Nathaniel S Chapman; Haiyan Zhao; Nurgun Kose; Jonna B Westover; Birte Kalveram; Robin Bombardi; Jessica Rodriguez; Rachel Sutton; Joseph Genualdi; A Desiree LaBeaud; Francis M Mutuku; Phillip R Pittman; Alexander N Freiberg; Brian B Gowen; Daved H Fremont; James E Crowe
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

6.  Role of EXT1 and Glycosaminoglycans in the Early Stage of Filovirus Entry.

Authors:  Aileen O'Hearn; Minxiu Wang; Han Cheng; Calli M Lear-Rooney; Katie Koning; Emily Rumschlag-Booms; Elizabeth Varhegyi; Gene Olinger; Lijun Rong
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

7.  Heparan Sulfate Proteoglycan Is an Important Attachment Factor for Cell Entry of Akabane and Schmallenberg Viruses.

Authors:  Shin Murakami; Akiko Takenaka-Uema; Tomoya Kobayashi; Kentaro Kato; Masayuki Shimojima; Massimo Palmarini; Taisuke Horimoto
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 8.  Alphaviruses suppress host immunity by preventing myeloid cell replication and antagonizing innate immune responses.

Authors:  Derek W Trobaugh; William B Klimstra
Journal:  Curr Opin Virol       Date:  2017-03-10       Impact factor: 7.090

Review 9.  Advances in the preparation and synthesis of heparin and related products.

Authors:  Sultan N Baytas; Robert J Linhardt
Journal:  Drug Discov Today       Date:  2020-09-16       Impact factor: 7.851

10.  Interplay between the Virus and Host in Rift Valley Fever Pathogenesis.

Authors:  Kaori Terasaki; Shinji Makino
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.